USPTO awards Immunitor frequency physical for viral vaccine

Insusceptible Network Ltd. (Pink Sheets:IMMFF), advises that its likely acquisition, Immunitor USA Inc., has been issued a key flagrant by the U.S. Patent and Trademark Support (USPTO).

The control (US 7,838,006 Viral vaccine medley, get ready and methods of use) contains claims covering the make-up of matter for Immunitor's head up yield, V5. The obvious also covers the manage of making and demand of the fact in support of treating and preventing the explicit series of catching diseases. Immunitor was thitherto awarded a U.S. explicit covering another preside over increase specifically designed an eye to treatment of AIDS (US 7,384,637).

According to Vichai Jirathitikal, the principal inventor on these two patents, The USPTO has validated the bauble and utility of Immunitor's technology and its use in the treatment and prophylaxis of a range of most distinctive diseases and conditions. The co-inventor, Aldar Bourinbaiar, Immunitor's CEO, added: With the i ssuance of these two patents, our be ahead of programs are again protected, significantly enhancing their commercial value.

To the advance of the throng's increase, Immunitor has achieved a broad and wise intellectual-property fix in the orally delivered immunotherapeutics area. The company's physical portfolio now includes more than eight inconclusive patents (including two ecumenical), with at least two dozen well-organized publications in the peer-reviewed medical publicity describing sundry aspects of the technology in infectious and autoimmune diseases, cancer, and metabolic diseases such as atherosclerosis and obesity. The combined annual store in the service of these and connected indications is wind up to $100 billion.

Immunitor is the effort commander in tableted oral vaccines and immunotherapies. During the close by three years Immunitor completed two insert II clinical trials using V5 against treatment of persistent hepatitis B and hepatitis C. This year Immunitor seized upon an unexpected clinical outcome, which revealed the intriguing dormant of V5 in curing tuberculosis in almost 95% of patients within a person month. The results of the beginning cipro antibiotic check in patients with tuberculosis who were co-infected with hepatitis C virus and HIV were published in October argue of Newsletter of Vaccines and Vaccination (http://www.omicsonline.org/2157-7560/2157-7560-1-103.php). Steadfast enrollment in compensation two additional phase 2b placebo-controlled trials involving 120 patients with difficult-to-treat forms of tuberculosis has been unprejudiced completed in Ukraine and results are anticipated in early 2011.

To appointment, all clinical trials of V5 be struck by provided indefatigable evidence of an excellent safeness vignette and provided insights into the unparalleled efficacy that thinks fitting guide Immunitor in the sketch out of follow-on hepatitis and tuberculosis studies, which are under being arranged in South Africa, Pakistan, India and China.

Unsusceptible Network is continuing its work toward caucus the pre-conditions object of fulfilment of a blending or comparable agreement with Immunitor. Various aspects of the updated corporation and its anticipated transactions will be announced early in December 2010.